Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Banks On Product Launches, OTC Switches For "Significant Growth"

This article was originally published in The Tan Sheet

Executive Summary

Perrigo is "poised for some significant growth" with $180 million in new product sales expected in the firm's current fiscal year, according to President and CEO Joseph Papa.
Advertisement

Related Content

Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
In Brief
Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Perrigo Gains Pole Position In Private-Label Allegra Race
Perrigo Grows Into Adjacent Infant Formula Category With PBM Acquisition
Perrigo Strives To Stand Out Against Incoming Private Label Competition
Zyrtec Launch Brings Big Boost To Johnson & Johnson, But Competition Grows

Topics

Advertisement
UsernamePublicRestriction

Register

PS104804

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel